Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Accumulated Expenses: 2010-2024

Historic Accumulated Expenses for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $247,159.

  • China Pharma Holdings' Accumulated Expenses fell 86.43% to $170,426 in Q3 2025 from the same period last year, while for Sep 2025 it was $170,426, marking a year-over-year decrease of 86.43%. This contributed to the annual value of $247,159 for FY2024, which is 17.29% down from last year.
  • According to the latest figures from FY2024, China Pharma Holdings' Accumulated Expenses is $247,159, which was down 17.29% from $298,829 recorded in FY2023.
  • China Pharma Holdings' 5-year Accumulated Expenses high stood at $404,807 for FY2022, and its period low was $177,359 during FY2020.
  • Over the past 3 years, China Pharma Holdings' median Accumulated Expenses value was $298,829 (recorded in 2023), while the average stood at $316,932.
  • In the last 5 years, China Pharma Holdings' Accumulated Expenses spiked by 68.28% in 2021 and then decreased by 26.18% in 2023.
  • Yearly analysis of 5 years shows China Pharma Holdings' Accumulated Expenses stood at $177,359 in 2020, then spiked by 68.28% to $298,452 in 2021, then surged by 35.64% to $404,807 in 2022, then declined by 26.18% to $298,829 in 2023, then decreased by 17.29% to $247,159 in 2024.